Compare Flux Power Holdings Inc (FLUX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs GSK plc — how do they compare? Flux Power Holdings Inc trades at $0.48 (market cap $9.97M), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 9215.6× Flux Power Holdings Inc's market cap, and GSK plc pays a 3.9% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 20 Days and GSK plc for 93 Days on average.
| FLUX | GSK | |
|---|---|---|
Market Cap | $9.97M | $91.88B |
Volume | 817,320 | 7,730,529 |
Sector | Industrials | Health |
52-Week High | $6.66 | $61.18 |
52-Week Low | $0.41 | $43.24 |
Typical Hold Time | 20 Days | 93 Days |
Enterprise Value | $18.18M | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.4612, down 5.92% today, with a bearish technical signal despite unanimous analyst buy ratings. The company reported declining revenue from $66M in 2025 to $42M in 2026 while maintaining a net loss of -$7M. Recent news highlights a rejected acquisition offer from Solidion Technology, creating uncertainty around strategic direction.
The stock faces fundamental challenges with negative profitability metrics but maintains a low P/S ratio of 0.22. Investment opportunity exists if operational improvements materialize, while risks include persistent losses and acquisition-related volatility. Analyst consensus remains optimistic with 6 buy ratings despite recent earnings misses.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
